2023.
. Systemic Lupus Erythematosus. A Clinician's Pearls & Myths in Rheumatology.Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. Arthritis Care and Research. 2023.
.Urine biomarker score captures response to induction therapy with lupus nephritis. Pediatric Nephrology. 2023.
.Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study. Arthritis Care and Research. 2023.
.Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Annals of the Rheumatic Diseases. 2023; 82:154-160.
.Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Journal of Rheumatology. 2023; 50:98-106.
.Race, ethnicity and patient-reported outcomes in childhood-onset systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2023; 41:186-194.
.Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research. 2022.
.2022.
. Juvenile idiopathic arthritis. .Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology. 2022; 20.
.Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. American Journal of Ophthalmology. 2022; 244:183-195.
.Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry. Pediatric Rheumatology. 2022; 20.
.Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology. 2022; 20.
.Cross-cultural adaptation and initial validation of the Brazilian-Portuguese version of the pediatric automated neuropsychological assessment metrics. Frontiers in Psychology. 2022; 13.
.Treatment Guidelines in Pediatric Rheumatic Diseases. Rheumatic Disease Clinics of North America. 2022; 48:725-746.
.Stability of novel urinary biomarkers used for lupus nephritis. Frontiers in Pediatrics. 2022; 10.
.Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis. Arthritis Care and Research. 2022; 74:1058-1064.
.Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Annals of the Rheumatic Diseases. 2022; 81:990-997.
.2022; 81:422.2-42423.
. POS0340 PREDICTORS OF CLINICAL RESPONSE TO ABATACEPT IN CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. Annals of the Rheumatic Diseases.2022; 81:145-146.
. OP0221 EFFICACY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA). Annals of the Rheumatic Diseases.Tofacitinib for juvenile idiopathic arthritis - Authors' reply. The Lancet. 2022; 399.
.Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus. Lupus Science and Medicine. 2022; 9.
.The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry. Frontiers in Medicine. 2022; 9.
.International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis and Rheumatology. 2022; 74:263-273.
.Biomarkers in Childhood-Onset Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America. 2022; 48:271-285.
.Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis. Lupus. 2022; 31:97-104.
.Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology. 2021; 19.
.Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology. 2021; 19.
.Impact of the Season of Birth on the Development of Juvenile Idiopathic Arthritis in the United States: A Nationwide Registry-based Study. Journal of Rheumatology. 2021; 48:1856-1862.
.Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. The Lancet. 2021; 398:1984-1996.
.2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine. 2021; 8.
.Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology. 2021; 60:4495-4507.
.Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology. 2021; 60:4568-4580.
.Clinicopathologic Conference: A Four-Year-Old Child With Digital Clubbing. Arthritis Care and Research. 2021; 73:1379-1386.
.Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. Arthritis and Rheumatology. 2021; 73:1910-1920.
.Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis and Rheumatology. 2021; 73:1898-1909.
.Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021; 7.
.Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2021; 73:1264-1274.
.Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. Journal of Rheumatology. 2021; 48:1322-1329.
.2021.
. Metrics and Outcome Measures of Disease Activity and Damage in Childhood-Onset Systemic Lupus Erythematosus. Outcome Measures and Metrics in Systemic Lupus Erythematosus.Evolution in the Understanding of Pediatric-Onset Axial Spondyloarthritis. Arthritis Care and Research. 2021; 73:921-923.
.Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. Journal of Rheumatology. 2021; 48:1073-1081.
.Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity. Kidney International Reports. 2021; 6:1949-1960.
.Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis. Arthritis Care and Research. 2021; 73:940-946.
.Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. Journal of Rheumatology. 2021; 48:852-858.
.Performance of the New 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults. Arthritis Care and Research. 2021; 73:580-585.
.Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. RMD Open. 2021; 7.
.Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. Arthritis and Rheumatology. 2021; 73:530-541.
.Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. Arthritis and Rheumatology. 2021; 73:336-346.
.Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease. Cytotherapy. 2021; 23:37-45.
.PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing. Frontiers in Pharmacology. 2020; 11.
.The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatric Rheumatology. 2020; 18.
.Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatric Rheumatology. 2020; 18.
.Cerebral microvascular and microstructural integrity is regionally altered in patients with systemic lupus erythematosus. Arthritis Research and Therapy. 2020; 22.
.Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study. Pediatric Rheumatology. 2020; 18.
.Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. Arthritis and Rheumatology. 2020; 72:2147-2158.
.Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. Arthritis Research and Therapy. 2020; 22.
.Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. Paediatric Drugs. 2020; 22:653-672.
.Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry. Arthritis Care and Research. 2020; 72:1636-1644.
.Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. Arthritis Care and Research. 2020; 72:1420-1430.
.Quality of Care in Childhood-onset Systemic Lupus Erythematosus: Report of an Intervention to Improve Cardiovascular and Bone Health Screening. Journal of Rheumatology. 2020; 47:1506-1513.
.Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Annals of the Rheumatic Diseases. 2020; 79:1340-1348.
.Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019. Pediatric Rheumatology. 2020; 18.
.Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. RMD Open. 2020; 6.
. . .SAGE Publications Ltd; SAGE Publications Ltd; 2020.
. Comparative Effectiveness Research Using Electronic Health Records Data: Ensure Data Quality. . :Development and pilot testing of the treatment and education approach for childhood-onset lupus (TEACH): a cognitive behavioral treatment. Pediatric Rheumatology. 2019; 17.
.Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFα withdrawal. Annals of the Rheumatic Diseases. 2019; 78:1712-1721.
.Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. Arthritis and Rheumatology. 2019; 71:1943-1954.
.Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. 2019; 49:251-259.
.Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. Journal of Rheumatology. 2019; 46:1117-1126.
.Update on the treatment and outcome of systemic lupus erythematous in children. Current Opinion in Rheumatology. 2019; 31:464-470.
.Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. Journal of Rheumatology. 2019; 46:1006-1013.
.Elevated serum complement levels and higher gene copy number of complement C4B are associated with hypertension and effective response to statin therapy in childhood-onset systemic lupus erythematosus (SLE). Lupus Science and Medicine. 2019; 6.
.American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. Arthritis Care and Research. 2019; 71:579-590.
.Proteomic profiling of urine: implications for lupus nephritis. Expert Review of Proteomics. 2019; 16:303-313.
.Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. Arthritis Care and Research. 2019; 71:482-491.
.2019; 58.
. 170 Safety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis. Rheumatology.Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Arthritis and Rheumatology. 2019; 71:451-459.
.Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. Annals of the Rheumatic Diseases. 2019; 78:162-170.
.Discovery of SERPINA3 as a candidate urinary biomarker of lupus nephritis activity. Rheumatology. 2019; 58:321-330.
.Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus. Pediatric Nephrology. 2019; 34:117-128.
.
Hermine I. Brunner, MD, MSc, MBA
Professor, UC Department of Pediatrics
Phone: 513-636-4676
Email: hermine.brunner@cchmc.org